NEWARK, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, ...
Thursday, CymaBay Therapeutics Inc (NASDAQ:CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due ...
ST GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions ...
At the 23rd Annual Scientific Sessions of the North American Society of Pacing and Electrophysiology (NASPE) held in San Diego, California, most of the discussion and analysis revolved around the ...
New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study Medtronic also announced ...
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback